

DAFTAR PUSTAKA

- Ackley, T.W., McManus, D., Topal, J.E., Cicali, B., dan Shah, S., 2021. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. *Antimicrobial Agents and Chemotherapy*, **65**: e02290-20.
- Adhikari SP, Meng S, Wu Y, Mao Y, Ye R, Wang Q, dkk, 2020, *A scoping review of 2019 Novel Coronavirus during the early outbreak period: Epidemiology, causes, clinical manifestation and diagnosis, prevention and control*. 2020;1–12.
- Alvarez, A.M. dan Mukherjee, D., 2011. Liver Abnormalities in Cardiac Diseases and Heart Failure. *The International Journal of Angiology: Official Publication of the International College of Angiology, Inc*, **20**: 135–142.
- Amirian ES, Levy JK., 2020, *Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses*, *One Heal*, 9(100128).
- Anderson, Gail D., 2008, *Chapter 1 Gender Differences in Pharmacological Response*, Vol 83, page 1-10, *International Review of Neurobiology*, DOI: 10.1016/S0074-7742(08)00001-9.
- Andrade, R.J., Aithal, G.P., Björnsson, E.S., Kaplowitz, N., Kullak-Ublick, G.A., Larrey, D., dkk., 2019. EASL Clinical Practice Guidelines: Drug-induced liver injury. *Journal of Hepatology*, **70**: 1222–1261.
- Andrade, R.J. dan Tulkens, P.M., 2011. Hepatic safety of antibiotics used in primary care. *Journal of Antimicrobial Chemotherapy*, **66**: 1431–1446.
- Anonim, 2012, Remdesivir, dalam: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
- Anonim, 2012, Tocilizumab, dalam: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
- Aslam M, Tan CK, Prayitno A, 2003, *Farmasi Klinis (Clinical Pharmacy), Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien*, Jakarta, Elex Media Komputindo. 2003. p. 18
- Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A., Al-Rabiah, F.A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W.N., Balkhy, H.H., Al-Hakeem, R.F. and Makhdoom, H.Q., 2013. *Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study*. *The Lancet*

infectious diseases, 13(9), pp.752-761. DOI: 10.1016/S1473-3099(13)70204-4

Bassi, Peter U., dkk., 2017, *Impact of Comorbidity on Adverse Drug Reaction Profile in A Cohort of Patients Treated With Artemisinin Combination Therapies For Uncomplicated Malaria in Nigeria*, *Pharma Res Per*, 5(2), 2017, e00302, DOI: 10.1002/prp2.302.

Beigel JH, Tomashek KM, Dodd, LE dkk., 2020, Remdesivir for the Treatment of Covid-19 - Preliminary Report. *The New England Journal of Medicine*. 2020 May. doi: 10.1056/NEJMoa2007764.

Bermejo-Martin, J. F., Kelvin, D. J., Eiros, J. M., Castrodeza, J., and Ortiz de Lejarazu, R. 2009. *Macrolides for the Treatment of Severe Respiratory Illness Caused by Novel H1N1 Swine Influenza Viral Strains*. *J. Infect. Dev. Ctries* 3 (3), 159–161. doi:10.3855/jidc.18

Bloom PP, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, dkk., 2020, *Liver Biochemistries in Hospitalized Patients With COVID-19*. *Hepatology* (Baltimore, Md), <http://dx.doi.org/10.1002/hep.31326>, 17 September 2021.

Bosso, M., Thanaraj, T.A., Abu-Farha, M., Alanbaei, M., Abubaker, J., dan Al-Mulla, F., 2020. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. *Molecular Therapy. Methods & Clinical Development*, **18**: 321–327.

BPOM, 2020, *Tingkatkan Angka Kesembuhan dan Turunkan Angka Kematian Pasien COVID-19, Badan POM Terbitkan Izin Penggunaan dalam Kondisi Darurat Obat Favipiravir dan Remdesivir*, <https://www.pom.go.id/new/view/more/pers/565>, 17 September 2021.

Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN, 2008, *Polypharmacy: misleading, but manageable*. *Clin Interv Aging* 3: 383–389.

Cai H, 2020, *Sex difference and smoking predisposition in patients with COVID-19*. *Lancet Respir Med* [Internet], 2020;8(4):e20.

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C. and Di Napoli, R., 2020. *Features, evaluation and treatment coronavirus (COVID-19)*. In *Statpearls* [internet]. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK554776/>

CDC: *Coronavirus Disease 2019 (COVID-19)*. In. Edited by Prevention CfDca, 2020, <https://www.cdc.gov/coronavirus/2019-ncov/symptomstesting/symptoms.html>.

Chandra, D., Palevsky, P., dan Scieurba, F.C., 2017. EnRAGEed Kidneys in Chronic Obstructive Pulmonary Disease? *American Journal of Respiratory and Critical Care Medicine*, **195**: 1411–1413.

- Chen, Y., Liu, Q. and Guo, D., 2020, Emerging coronaviruses: genome structure, replication, and pathogenesis. *Journal of medical virology*, 92(4), pp.418-423. DOI: 10.1002/jmv.25681.
- Coresh, J., Wei, G.L., McQuillan, G., Brancati, F.L., Levey, A.S., Jones, C., dkk., 2001. Prevalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States: Findings From the Third National Health and Nutrition Examination Survey (1988-1994). *Archives of Internal Medicine*, **161**: 1207–1216.
- Dabla, P.K., 2010. Renal function in diabetic nephropathy. *World Journal of Diabetes*, **1**: 48–56.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia, 2020, *Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19)*, Maret 2020, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Drugs.com, 2021, *Remdesivir Side Effects*, <https://www.drugs.com/sfx/remdesivir-side-effects.html>, 14 September 2021.
- EMA, 2020, *First COVID-19 treatment recommended for EU authorisation*. European Medicines Agency, <https://www.ema.europa.eu/en/news/update-remdesivir-ema-will-evaluate-new-data-solidarity-trial>, 14 September 2021.
- Ferner FE, Butt TF. Adverse Drug Reactions. *Clin Pharmacol Med*. 2012;40:7.
- Firdausy A., Fatoni A., Fitrianiingsih A., dkk, 2021, *The Covidpedia*, Malang, Media Nusa Creative.
- Fisher, M. dkk, 2020, *AKI in hospitalized patients with and without COVID-19: a comparison study*. *J. Am. Soc. Nephrol*. 31, 2145– 2157.
- Food and Drug Administration, 2015, *Medicines and You: A Guide For Older Adults*. <https://www.fda.gov/drugs/resources-you-drugs/medicines-and-you-guide-older-adults>, 13 September 2021.
- Food and Drug Administration, 2020, *Emergency Use Authorization for Remdesivir*, <https://www.fda.gov/media/137564/download>, 13 September 2021.
- Fu L, Wang B, Yuan T, dkk., 2020, *Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and metaanalysis*, *J Infect*;80(6):656-665.
- Gao Y., T. Li, M. Han, X. Li, D. Wu, Y. Xu, Y. Zhu, Y. Liu, X. Wang, L. Wang, 2020, *Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19*, *J Med Virol.*, <https://doi.org/10.1002/jmv.25770>.

- Goldman, J.D. dkk., 2020, *Remdesivir for 5 or 10 days in patients with severe COVID-19*. N. Engl. J. Med. 383, 1827–1837.
- Gordon, C. J.; Tchesnokov, E. P.; Woolner, E.; Perry, J. K; Feng, J. Y.; Porter, D. P; Gotte, M., 2020, *Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency*, J. Biol. Chem., jbc.RA120.013679.
- Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, dkk. *Clinical characteristics of coronavirus disease 2019 in China*. N Engl J Med. 2020;382(18):1708–20.
- Guy, J. dan Peters, M.G., 2013. Liver Disease in Women: The Influence of Gender on Epidemiology, Natural History, and Patient Outcomes. *Gastroenterology & Hepatology*, **9**: 633–639.
- Hajjar ER, Hanlom JT, Margaret, Lindblad CI, Pieper CF, Sloane RJ, Ruby C, Schmader K. *Adverse Drug Reactions in Older Outpatients*. *The American Journal of Geriatric Pharmacotherapy*. 2003;1:2 10. Indian J Med Res.2012;136(3): 404±410.
- Hamid, S., Mir, M.Y. and Rohela, G.K., 2020, Novel coronavirus disease (COVID-19): A pandemic (Epidemiology, Pathogenesis and potential therapeutics). *New Microbes and New Infections*, p.100679. DOI: 10.1016/j.nmni.2020.100679.
- Holshue, M.L., DeBolt, C., Lindquist, S., Lofy, K.H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A. and Diaz, G., 2020, First case of 2019 novel coronavirus in the United States. *New England Journal of Medicine*. DOI: 10.1056/NEJMoa2001191.
- Jeronimo, C. M. P., Farias, M. E. L., Val, F. F. A., et al. 2020. *Methylprednisolone as Adjunctive Therapy for Patients Hospitalized with COVID-19 (Metcovid): A Randomised, Double-Blind, Phase Iib, Placebo-Controlled Trial*. *Clin. Infect. Dis.* 72, e373. doi:10.1093/cid/ciaa1177
- J.S. Morse, T. Lalonde, S. Xu, W.R. Liu, 2020, *Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV*, *Chembiochem*. 21 (5) 730–738, <https://doi.org/10.1002/cbic.202000047>.
- KDIGO, K., 2012. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney International Supplements*, **2**: 1.
- Khumar and Al Khodor, 2020, Pathophysiology and treatment strategies for COVID-19, *Journal of Translational Medicine*, pp 9, doi.org/10.1186/s12967-020-02520-8.
- Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D., 2004, *Complex drug–drug–disease interactions between Amiodarone, Warfarin, and the thyroid gland*. *Medicine* 83: 107–113.

- Lei, J., Li, J., Li, X. and Qi, X., 2020. *CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology*, 295(1), pp.18-18. DOI: 10.1148/radiol.2020200236
- Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, dkk., 2020, *Coronavirus infections and immune responses. J Med Virol.* 2020;92(4):424–32.
- Li X, Geng M, Peng Y, Meng L, Lu S. *Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal.* 2020;10(2):102–8.
- Liang W, Guan W, Chen R, Wang W, Li J, Xu K, dkk. *Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol.* 2020;21(3):335–7.
- Lin, S. J., Kuo, M. L., Hsiao, H. S., and Lee, P. T. 2016. *Azithromycin Modulates Immune Response of Human Monocyte-Derived Dendritic Cells and CD4+ T Cells. Int. Immunopharmacol* 40, 318–326. doi:10.1016/j.intimp.2016.09.012.
- Lövborg H, Eriksson LR, Jönsson AK, Bradley T, Hägg S. *A Prospective Analysis Of The Preventability Of Adverse Drug Reactions Reported In Sweden. Eur J Clin Pharmacol.* 2012;68:1183±1189.
- Lu, H., 2020, Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Bioscience trends*, 14(1), pp.69-71. DOI: 10.5582/bst.2020.01020.
- Mänttari, M., Tiula, E., Alikoski, T., dan Manninen, V., 1995. Effects of Hypertension and Dyslipidemia on the Decline in Renal Function. *Hypertension*, 26: 670–675.
- Min, J., and Jang, Y. J. 2012. *Macrolide Therapy in Respiratory Viral Infections. Mediators Inflamm.* 2012, 649570. doi:10.1155/2012/649570.
- Muaed, JA., 2012, *Factors affecting the development of adverse drug reactions (Review article). Saudi Pharmaceutical Journal.* 22: 83–94.
- Noguchi, S., Yatera, K., Kawanami, T., Yamasaki, K., Uchimura, K., Hata, R., et al. 2014. *Efficacy and Safety of Azithromycin Infusion in Patients with Mild or Moderate Community-Acquired Pneumonia. Jpn. J. Antibiot.* 67 (3), 193–203.
- Obreli-Neto PRO, Nobili A, Baldoni AO, Guidoni CM, Junior DPL, Pilger D, Duzanski J, Tettamanti M, Souza JMC, Gaeti WP, Cuman RKN. 2012. *Adverse Drug Reactions Caused by Drug-Drug Interactions in Elderly Outpatients: A Prospective Cohort Study. Eur J Clin Pharmacol.* 68(3):1667-1676
- Oh, R. C., Hustead, T.R., Ali, S. M., dan Pantsari, M.W. 2017. Mildly Elevated Liver Transaminase Levels: Cause and Evaluation. *American Family Physician.* 96: 706-715.

- PDPI, PERKI, PAPDI, PERDATIN, IDAI, 2022, *Pedoman Tatalaksana COVID-19 Edisi 4*, PDPI, PERKI, PAPDI, PERDATIN, IDAI, Jakarta.
- Perhimpunan Dokter Paru Indonesia (PDPI), 2020, *Pneumonia COVID-19, Diagnosis & Penatalaksanaan Di Indonesia*, hal 3, Perhimpunan Dokter Paru Indonesia, Jakarta.
- Phan, L.T., Nguyen, T.V., Luong, Q.C., Nguyen, T.V., Nguyen, H.T., Le, H.Q., Nguyen, T.T., Cao, T.M. and Pham, Q.D., 2020. *Importation and human-to-human transmission of a novel coronavirus in Vietnam*. *New England Journal of Medicine*, 382(9), pp.872-874. DOI: 10.1056/NEJMc2001272
- PubChem, 2021, *PubChem Compound Summary for CID 121304016, Remdesivir*, <https://pubchem.ncbi.nlm.nih.gov/compound/Remdesivir>, 12 September 2021.
- Rahman, S., Islam, S., Haque, T., Kathak, R.R., dan Ali, N. 2020. Association between serum liver enzymes and hypertension: a cross-sectional studi in Bangladeshi adults. *BMC Cardiovascular Disorder*, **20**: 128.
- Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A, 2012, *A Survey on Polypharmacy and Use of Inappropriate Medications*. *Toxicol Int* 19: 68–73.
- Rothan, H.A. dan Byrareddy, S.N., 2020. The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. *Journal of Autoimmunity*, p.102433. DOI: 10.1016/j.jaut.2020.102433
- Satuan Tugas Penanganan COVID-19, 2021, *Peta Sebaran COVID-19*, <https://covid19.go.id/peta-sebaran-covid19>, 10 September 2021.
- Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, dkk., 2020, *Coronavirus Disease 2019: Tinjauan Literatur Terkini. Penyakit Dalam Indonesia*;7(1):45.
- Tim Kerja Kementerian Dalam Negeri untuk Dukungan Gugus Tugas COVID-19, 2020, *Pedoman Umum Menghadapi Pandemi COVID-19 bagi Pemerintah Daerah: Pencegahan, Pengendalian, Diagnosis, dan Manajemen*, Kementerian Dalam Negeri Republik Indonesia, Jakarta, diakses di [https://www.kemendagri.go.id/documents/covid-19/BUKU PEDOMAN COVID-19 KEMENDAGRI.pdf](https://www.kemendagri.go.id/documents/covid-19/BUKU_PEDOMAN_COVID-19_KEMENDAGRI.pdf) 11 September 2021.
- Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, dkk., 2020, *Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1*. *N Engl J Med*, 382:1564-7.
- Van Laar, S.A.; de Boer, M.G.J.; Gombert-Handoko, K.B.; Guchelaar, H.J.; Zwaveling, J.; *LUMC-Covid-19 Research Group. Liver and kidney function in patients with Covid-19 treated with remdesivir*. *Br. J. Clin. Pharmacol.* 2021.

- Viglino, D., Jullian-Desayes, I., Minoves, M., Aron-Wisnewsy, J., Leroy, V., Zarski, J.-P., dkk., 2017. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. *European Respiratory Journal*, **49**: 1601923.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, dkk. *Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China*. *JAMA - J Am Med Assoc*. 2020;323(11):1061–9.
- Wang M, Cao R, Zhang L, dkk., 2020, *Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro*, *Cell Res*; 30: 2–71.
- WHO, 2020, *WHO Coronavirus Disease (COVID-19) Dashboard*, <https://covid19.who.int/>, 13 September 2021.
- WHO, 2021, *Indonesia: WHO Coronavirus Disease (COVID-19) Dashboard*, <https://covid19.who.int/region/searo/country/id>, 10 September 2021.
- Williamson, B. N. dkk. 2020, *Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2*, *Nature*. doi: 10.1038/s41586-020-2423-5.
- Wulandari, N., Andrajati, R., dan Supardi, S., 2016. Faktor Risiko Umur Lansia terhadap Kejadian Reaksi Obat yang Tidak Dikehendaki pada Pasien Hipertensi, Diabetes, Dislipidemia di Tiga Puskesmas di Kota Depok. *Jurnal Kefarmasian Indonesia*, **6**: 60–67.
- Zhang, X., Cai, H., Hu, J., Lian, J., Gu, J., Zhang, S., Ye, C., Lu, Y., Jin, C., Yu, G. and Jia, H., 2020, *Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings*, *International Journal of Infectious Diseases*, diakses di <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270493/>, 10 September 2021.
- Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. *Reducing mortality from 2019-nCoV: host-directed therapies should be an option*. *Lancet* [Internet]. 2020;395(10224):e35–6.